menu ☰
menu ˟

Merck halts development of anacetrapib

12 Oct 2017
Merck has announced that applications will not be submitted for regulatory approval of anacetrapib, a cholesteryl ester transfer protein inhibitor for the treatment of patients with CVD.Numerous studies have shown that anacetrapib not only raises HDL...

Click here to view the full article which appeared in Cardiology

IPH Logo